Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PIE
|
|||
| Drug Name |
Brigatinib
|
|||
| Synonyms |
1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaplastic large cell lymphoma [ICD-11: 2A90.A; ICD-10: C84.6] | Approved | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Approved | [2] | ||
| Company |
Ariad Pharmaceuticals/Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H39ClN7O2P
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
|
|||
| InChI |
1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
|
|||
| InChIKey |
AILRADAXUVEEIR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1197953-54-0
|
|||
| PubChem Compound ID | ||||
| ADReCS Drug ID | BADD_D02509 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ALK tyrosine kinase receptor (ALK) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Non-small cell lung cancer | |||
| WikiPathways | Differentiation Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.